Current Report Filing (8-k)
March 02 2018 - 10:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
March 2, 2018 (February 27, 2018)
BIOSCRIP,
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-11993
|
05-0489664
|
(State or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(Employer Identification Number)
|
|
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(720) 697-5200
(Registrant's telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
Emerging growth company
|
|
¨
|
|
|
|
|
|
|
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
¨
|
Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 27, 2018, BioScrip, Inc. (the
“Company”), announced that Vice President, Chief Accounting Officer and Controller Anthony Lopez is on a temporary
leave of absence. In Mr. Lopez’s absence, Alex Schott, the Company’s Senior Vice President, Strategic Operations will act as the
Company’s principal accounting officer.
Mr. Schott joined the Company in September 2016.
From 2014 until joining the Company, Mr. Schott was the Chief Financial Officer for Home Solutions and was responsible for leading
accounting, finance, treasury, reimbursement, and economic strategy and forecasting. From 2010 to 2014, Mr. Schott served as Vice
President of Finance for Lanx, Inc., an international medical device company that was acquired in 2013 by Biomet, Inc., a global
manufacturer of musculoskeletal and biotechnology products. Mr. Schott served as Director of Accounting at Coram Specialty Infusion
Services from 2000-2005 and as Vice President and Controller from 2005 until 2009.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
Date: March 1, 2018
|
|
|
|
|
By:
|
/s/ Kathryn M.
Stalmack
|
|
|
Kathryn M.
Stalmack
Senior Vice President,
General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024